All Stories

  1. Amino acid management of Parkinson's disease: a case study [Corrigendum]

    Article • International Journal of General Medicine, June 2016, Dove Medical Press

    Alvin Stein, marty hinz

  2. Parkinson's disease managing reversible neurodegeneration [Corrigendum]

    Article • June 2016, Dove Medical Press

    Dr Ted Cole, Dr Mark Westaway, marty hinz

  3. Parkinson’s disease managing reversible neurodegeneration

    Article • April 2016, Dove Medical Press

    Dr Ted Cole, Dr Mark Westaway, marty hinz

  4. Relative nutritional deficiencies associated with centrally acting monoamines [Corrigendum]

    Article • International Journal of General Medicine, April 2015, Taylor & Francis

    Alvin Stein, marty hinz

  5. Parkinson’s disease-associated melanin steal

    Article • December 2014, Taylor & Francis

    Alvin Stein, Dr Ted Cole, marty hinz

  6. Parkinson's disease: carbidopa, nausea, and dyskinesia

    Article • Clinical Pharmacology Advances and Applications, November 2014, Taylor & Francis

    Alvin Stein, Dr Ted Cole, marty hinz

  7. The Parkinson's disease death rate: carbidopa and vitamin B6

    Article • Clinical Pharmacology Advances and Applications, October 2014, Taylor & Francis

    Alvin Stein, Dr Ted Cole, marty hinz

  8. Tyrosine does not cause increased blood pressure

    Article • Clinical Pharmacology Advances and Applications, July 2014, Taylor & Francis

    Alvin Stein, Dr Ted Cole, marty hinz

  9. Management of L-dopa overdose in the competitive inhibition state

    Article • Drug Healthcare and Patient Safety, July 2014, Taylor & Francis

    Alvin Stein, Dr Ted Cole, marty hinz

  10. 5-HTP efficacy and contraindications

    Article • Neuropsychiatric Disease and Treatment, July 2012, Taylor & Francis

    Alvin Stein, marty hinz

  11. Relative nutritional deficiencies associated with centrally acting monoamines

    Article • International Journal of General Medicine, May 2012, Taylor & Francis

    Alvin Stein, marty hinz

  12. The discrediting of the monoamine hypothesis

    Article • International Journal of General Medicine, February 2012, Taylor & Francis

    Alvin Stein, marty hinz

  13. Monoamine depletion by reuptake inhibitors

    Article • Drug Healthcare and Patient Safety, October 2011, Taylor & Francis

    Alvin Stein, marty hinz

  14. APRESS: apical regulatory super system, serotonin, and dopamine interaction

    Article • Neuropsychiatric Disease and Treatment, August 2011, Taylor & Francis

    Alvin Stein, marty hinz

  15. Validity of urinary monoamine assay sales under the “spot baseline urinary neurotransmitter testing marketing model”

    Article • International Journal of Nephrology and Renovascular Disease, July 2011, Taylor & Francis

    Alvin Stein, marty hinz

  16. Amino acid management of Parkinson’s disease: a case study

    Article • International Journal of General Medicine, February 2011, Taylor & Francis

    Alvin Stein, marty hinz

  17. Treatment of attention deficit hyperactivity disorder with monoamine amino acid precursors and organic cation transporter assay interpretation

    Article • Neuropsychiatric Disease and Treatment, January 2011, Taylor & Francis

    Alvin Stein, marty hinz

  18. Amino acid-responsive Crohn's disease: a case study

    Article • Clinical and Experimental Gastroenterology, December 2010, Taylor & Francis

    Alvin Stein, marty hinz

  19. A pilot study differentiating recurrent major depression from bipolar disorder cycling on the depressive pole

    Article • Neuropsychiatric Disease and Treatment, November 2010, Taylor & Francis

    Alvin Stein, marty hinz

  20. The dual-gate lumen model of renal monoamine transport

    Article • Neuropsychiatric Disease and Treatment, July 2010, Taylor & Francis

    Alvin Stein, marty hinz